198480-55-6

Basic information

• Product Name: PIPENDOXIFENE
• Synonyms: PIPENDOXIFENE;ERA 923;2-(4-hydroxyphenyl)-3-methyl-1-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]indol-5-ol
• CAS NO: 198480-55-6
• Molecular Formula: C29H32N2O3
• Molecular Weight: 456.583
• Mol File: 198480-55-6.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 685.8°Cat760mmHg
• Flash Point: 368.6°C
• Appearance: /
• Density: 1.2g/cm³
• Vapor Pressure: 1.93E-19mmHg at 25°C
• Refractive Index: 1.628
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 10.12±0.15(Predicted)
• CAS DataBase Reference: PIPENDOXIFENE(CAS DataBase Reference)
• NIST Chemistry Reference: PIPENDOXIFENE(198480-55-6)
• EPA Substance Registry System: PIPENDOXIFENE(198480-55-6)

Safety Data

• Hazardous Substances Data: 198480-55-6(Hazardous Substances Data)

Usage

Uses

Pipendoxifene is a 2-Ph indole selective estrogen receptor modulator (SERM) that exhibits an excellent preclin. pharmacol. profile and was selected for further development as a treatment for metastatic breast cancer.

InChI:InChI=1/C29H32N2O3/c1-21-27-19-25(33)11-14-28(27)31(29(21)23-7-9-24(32)10-8-23)20-22-5-12-26(13-6-22)34-18-17-30-15-3-2-4-16-30/h5-14,19,32-33H,2-4,15-18,20H2,1H3

Relevant articles and documents

2-PHENYL-1-[-(2-AMINOETHOXY)-BENZYL -INDOLE IN COMBINATION WITH ESTROGENS

-

Combination therapy for inhibiting sphincter incontinence

This invention comprises methods of inducing or maintaining sphincter continence, or inhibiting or alleviating incontinence, in a mammal comprising administration of a compound of the formulae I or II: wherein Z is a moiety selected from the group of: wherein: R1 is selected from H, OH or the C1-C12 esters or C1-C12 alkyl ethers thereof, benzyloxy, or halogens; or C1-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R2, R3, R4, R5, and R6 are H, OH or C1-C12 esters or C1-C12 alkyl ethers thereof, halogens, or C1-C4 halogenated ethers, cyano, C1-C6 alkyl, or trifluoromethyl, with the proviso that, when R1 is H, R2 is not OH; Y is the moiety: R7 and R8 are alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring; or a pharmaceutically acceptable salt thereof.

Methods of treating excessive intraocular pressure

This invention comprises methods of treatment, prevention, inhibition or alleviation of the problems associated with excessive intraocular pressure comprising administration of a compound of the formulae I or II: wherein Z is a moiety selected from the group of: wherein: R1 is selected from H, OH or the C1-C12 esters or C1-C12 alkyl ethers thereof, or halogens; or C1-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R2, R3, R4, R5, and R6 are H, OH or C1-C12 esters or C1-C12 alkyl ethers thereof, halogens, or C1-C4 halogenated ethers, cyano, C1-C6 alkyl, or trifluoromethyl, with the proviso that, when R1 is H, R2 is not OH; Y is the moiety: R7 and R8 are alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring; or a pharmaceutically acceptable salt thereof.